In this thoughtful commentary, Octane leaders and scientists Tim Smith, Alexis Pietak and Nuala Trainor discuss how major challenges in the Good Manufacturing Practice (GMP) production of clinically significant numbers of autologous adult stem cells can be addressed by automated cell culture “GMP-in-a-box” systems. Such an approach may result in a distributed, decentralized model where personalized cell therapies are produced at point-of-care in primary care facilities.
Nature Biotechnology, 32, 729–735 (2014)
Authors: Nuala Trainor, Alexis Pietak and Tim Smith
We’re advancing personalized cell therapy as the standard of care through a partnership between Octane Biotech and the Lonza Group
How can automated bioreactor technology accelerate the commercialization of cell and tissue therapy products for regenerative medicine? This scientific article co-authored by Octane CEO Tim Smith lays out a roadmap highlighting why and how bioreactors must be implemented throughout the development of engineered tissue products, allowing scientific, medical, ...
August 3, 2009
Along with two other researchers, Octane scientist Alexis Pietak examines the crystallization kinetics in the transformation of an unfired hydroxyapatite precipitate (HA) into silicon stabilized tri-calcium phosphate (Si-TCP) – a bioceramic with attributes that make it a viable material in next-generation implants. Journal of Materials Science, 39, 2443–2449 ...
April 24, 2004
Silicon stabilized tricalcium phosphate [Si-TCP] is a bioceramic of major biological interest because of its osteoconductivity and unique influence on skeletal tissue repair and remodelling. In this research paper co-authored by Octane CEO Tim Smith, scientists explain how Si-TCP is formed within the calcium hydroxyapatite (HA)—tricalcium phosphate (TCP) ...
February 3, 2002